The study found that CAPHOSOL results in a low incidence of oral mucositis, moderate to severe pain, and dysphagia. Patient satisfaction rates were high, with 79% describing themselves as satisfied or very satisfied with the treatment.
The study found that CAPHOSOL treatment significantly limits the occurrence and severity of oral mucositis, with high levels of medication compliance and patient/physician satisfaction reported. Compliance was very high, with nearly all patients rinsing with CAPHOSOL at least once daily.
A study showed that Caphosol use led to lower OM rates and severity, as well as low pain medication use and high patient satisfaction among cancer patients. High efficacy ratings were also reported by physicians.
CAPHOSOL, an advanced electrolyte solution, has been shown to relieve oral mucositis and improve quality of life for cancer patients. The study found that 95% of patients reported favorable OM scores and high levels of patient and practitioner satisfaction with CAPHOSOL.